Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Active not recruiting 5

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 31Gastrointestinal 24Thoracic 16Head & Neck 9Tumor-Agnostic 7Sarcoma 6Other solid neoplasm 5Dermatologic 5Breast 5Genitourinary 3CNS 3Plasma cell 2Endocrine 2Lymphoid 1

Conditions

Melanoma 4Skin Neoplasms 1Rhabdomyosarcoma 1Osteosarcoma 1Neoplasms 1Lung Neoplasms 1Hodgkin Disease 1Hepatoblastoma 1Head and Neck Neoplasms 1Glioblastoma 1Fibrolamellar hepatocellular carcinoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 193aldesleukin 145Interleukin-2 109fludarabine phosphate 106Temozolomide 83Dacarbazine 81fludarabine 80Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Carboplatin 48Magnetic Resonance Spectroscopy 47Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × dostarlimab × Dermatologic × Clear all
NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

University of Southern California

Phase 1 Active not recruiting
10 enrolled
Dermatologic

Skin Neoplasms

NCT06521567 2025-11-12

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

GlaxoSmithKline

Phase 1/2 Active not recruiting
83 enrolled
CNSDermatologicGastrointestinalLymphoidSarcoma

Fibrolamellar hepatocellular carcinoma, Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Melanoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma

NCT02817633 2025-10-28

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Tesaro, Inc.

Phase 1 Active not recruiting
463 enrolled
DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

NCT04139902 2025-10-15

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

University of Pittsburgh

Phase 2 Active not recruiting
48 enrolled
Dermatologic

Melanoma

NCT05060432 2024-06-21

TIG-006

iTeos Therapeutics

Phase 1/2 Active not recruiting
153 enrolled
DermatologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡